U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments
BLA FilingEnspryngPositive
AI Analysis
Summary
Roche received FDA Priority Review for Enspryng (satralizumab) as a supplemental BLA for MOGAD treatment, based on positive Phase III METEOROID study results. FDA decision expected by January 10, 2027.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Priority Review granted for supplemental Biologics License Application
Importance:8/10
Sentiment:
0.85
FDA approvalPriority ReviewEnspryngMOGADautoimmune diseaseorphan indicationPhase 3 positive
Related Companies
Read the original article
Published by GlobeNewswire Pharma on September 10, 2026 5:00 AM